These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24460647)

  • 21. Peri-operative third party red blood cell transfusion in renal transplantation and the risk of antibody-mediated rejection and graft loss.
    Fidler S; Swaminathan R; Lim W; Ferrari P; Witt C; Christiansen FT; D'Orsogna LJ; Irish AB
    Transpl Immunol; 2013 Dec; 29(1-4):22-7. PubMed ID: 24090807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.
    Davin JC; Gracchi V; Bouts A; Groothoff J; Strain L; Goodship T
    Am J Kidney Dis; 2010 Apr; 55(4):708-11. PubMed ID: 19854549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.
    Sellier-Leclerc AL; Fremeaux-Bacchi V; Dragon-Durey MA; Macher MA; Niaudet P; Guest G; Boudailliez B; Bouissou F; Deschenes G; Gie S; Tsimaratos M; Fischbach M; Morin D; Nivet H; Alberti C; Loirat C;
    J Am Soc Nephrol; 2007 Aug; 18(8):2392-400. PubMed ID: 17599974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
    Fakhouri F; Delmas Y; Provot F; Barbet C; Karras A; Makdassi R; Courivaud C; Rifard K; Servais A; Allard C; Besson V; Cousin M; Châtelet V; Goujon JM; Coindre JP; Laurent G; Loirat C; Frémeaux-Bacchi V
    Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful renal transplantation in a patient with atypical hemolytic uremic syndrome carrying mutations in both factor I and MCP.
    Cruzado JM; de Córdoba SR; Melilli E; Bestard O; Rama I; Sánchez-Corral P; López-Trascasa M; Navarro I; Torras J; Gomà M; Grinyó JM
    Am J Transplant; 2009 Jun; 9(6):1477-83. PubMed ID: 19459807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peri- and Post-operative Evaluation and Management of Atypical Hemolytic Uremic Syndrome (aHUS) in Kidney Transplantation.
    Java A
    Adv Chronic Kidney Dis; 2020 Mar; 27(2):128-137. PubMed ID: 32553245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report.
    Dedhia P; Govil A; Mogilishetty G; Alloway RR; Woodle ES; Abu Jawdeh BG
    Transplant Proc; 2017; 49(1):188-192. PubMed ID: 28104134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation.
    Ranch D; Crowther B; Arar M; Assanasen C
    Pediatr Transplant; 2014 Sep; 18(6):E185-9. PubMed ID: 24931815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atypical hemolytic uremic syndrome: update on the complement system and what is new.
    Hirt-Minkowski P; Dickenmann M; Schifferli JA
    Nephron Clin Pract; 2010; 114(4):c219-35. PubMed ID: 20090363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis.
    Szarvas N; Szilágyi Á; Tasic V; Nushi-Stavileci V; Sofijanova A; Gucev Z; Szabó M; Szabó A; Szeifert L; Reusz G; Rusai K; Arbeiter K; Müller T; Prohászka Z
    Ital J Pediatr; 2014 Dec; 40():101. PubMed ID: 25496981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM; Brophy PD
    Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eculizumab in renal transplantation.
    Legendre C; Sberro-Soussan R; Zuber J; Rabant M; Loupy A; Timsit MO; Anglicheau D
    Transplant Rev (Orlando); 2013 Jul; 27(3):90-2. PubMed ID: 23747093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome.
    Richards A; Kathryn Liszewski M; Kavanagh D; Fang CJ; Moulton E; Fremeaux-Bacchi V; Remuzzi G; Noris M; Goodship TH; Atkinson JP
    Mol Immunol; 2007 Jan; 44(1-3):111-22. PubMed ID: 16882452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits.
    Boyer O; Noël LH; Balzamo E; Guest G; Biebuyck N; Charbit M; Salomon R; Frémeaux-Bacchi V; Niaudet P
    Am J Kidney Dis; 2008 Apr; 51(4):671-7. PubMed ID: 18371543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome.
    Fremeaux-Bacchi V; Moulton EA; Kavanagh D; Dragon-Durey MA; Blouin J; Caudy A; Arzouk N; Cleper R; Francois M; Guest G; Pourrat J; Seligman R; Fridman WH; Loirat C; Atkinson JP
    J Am Soc Nephrol; 2006 Jul; 17(7):2017-25. PubMed ID: 16762990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of thrombocytopaenia and/or microangiopathic haemolytic anaemia does not reliably exclude recurrence of atypical haemolytic uraemic syndrome after kidney transplantation.
    Krishnan AR; Siva B; Chakera A; Wong G; Wong D; Lim WH
    Nephrology (Carlton); 2017 Feb; 22 Suppl 1():28-31. PubMed ID: 28176477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
    Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
    Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab.
    Noone D; Al-Matrafi J; Tinckam K; Zipfel PF; Herzenberg AM; Thorner PS; Pluthero FG; Kahr WH; Filler G; Hebert D; Harvey E; Licht C
    Am J Transplant; 2012 Sep; 12(9):2546-53. PubMed ID: 22681773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Shared molecular eplet stimulates acute antibody-mediated rejection in a kidney transplant recipient with low-level donor-specific antibodies: a case report.
    Mongkolsuk T; Ingsathit A; Worawichawong S; Jirasiritham S; Kitpoka P; Thammanichanond D
    Transplant Proc; 2014; 46(2):644-7. PubMed ID: 24656035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathologic characteristics and outcomes of late acute antibody-mediated rejection in Thai kidney transplant recipients: a single-center experience.
    Larpparisuth N; Premasathian N; Vareesangthip K; Cheunsuchon B; Parichatikanon P; Vongwiwatana A
    Transplant Proc; 2014; 46(2):477-80. PubMed ID: 24655993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.